Bionanoparticle Analysis System

ExoView R100是一种新的商业设备，可以分析和表征细胞外小泡(EVS)。电动汽车是一种球形纳米颗粒，由大多数细胞分泌，从简单的细菌细胞到构成复杂生物(如人类)的细胞。新出现的证据表明，EVS具有生物活性，并形成了一种重要的、但以前未知的细胞间通信模式的基础，该模式有助于组织发育、维护、再生和衰老等关键过程。它们的强大功能刺激了一个新的但快速增长的研究领域，致力于开发基于EV的应用，包括将其用作疫苗和药物递送剂，以及诊断和治疗细菌/病毒感染、癌症和退行性疾病。 这里描述的研究计划在加拿大是独一无二的，将解决这一新兴领域的两个主要瓶颈：(1)试图开发新应用的研究人员需要但没有机会接触到大量具有明确物理和功能特征的电动汽车。目前，EV种群只能从自然来源或小规模细胞培养中分离出来，而且异质性很强，数量有限。我们将利用我们在开发生物反应器协议方面的丰富经验来生产定义的成体干细胞(ASC)群体，现在将设计可放大的过程，用于可重复生成的靶向ASC来源的电动汽车。越来越多的人认为，ASCs植入治疗疾病后报告的许多积极结果实际上可能是由于细胞产生的EVS。我们的计划将产生强大的生物过程，能够向试图开发针对人类和动物疾病的新疗法的研究人员提供大量已定义的电动汽车。(2)目前收集电动汽车的方法效率低下，高度依赖用户，并导致非常低的收益率。我们已经在开发一种简单且经济高效的微流控设备方面取得了进展，该设备可以在高流速下高效且可重复地从生物液和细胞培养液中分离和分离EV。我们计划进一步完善这项技术，因为它有可能成为这一快速增长领域的所有研究人员使用的标准电动汽车分离过程。 所要求的ExoView R100可以准确地量化电动汽车，并在物理/功能上表征电动汽车。该设备在加拿大将是独一无二的，它将使我们能够开发、验证和转化我们的电动汽车生产和分离技术，并对确保该研究计划的进展和成功至关重要。通过提供培训，来自卡尔加里大学内外不同学科的不同和快速增长的电动汽车研究人员小组将可以访问ExoView。由此产生的技术和训练有素的人员将有助于加拿大成为这一令人兴奋的新领域的全球领导者。

The ExoView R100 is a new commercial device which can analyze and characterize extracellular vesicles (EVs). EVs are spherical nanoparticles that are secreted by most cells, ranging from simple bacterial cells to those that make up complex organisms such as humans. Emerging evidence suggests that EVs are bioactive and form the basis for an important, but previously unknown mode of communication between cells, that contributes to critical processes including tissue development, maintenance, regeneration and aging. Their powerful functionality has spurred a new, but rapidly growing field of research dedicated to developing EV-based applications, including using them as vaccines and drug delivery agents, and to diagnose and treat bacterial/viral infections, cancers and degenerative conditions. The research program described here is unique in Canada and will address two major bottlenecks in this emerging field: (1) Researchers who are attempting to develop new applications require, but do not have, access to large numbers of EVs with defined physical and functional characteristics. Currently, EV populations can only be isolated from natural sources or small-scale cell culture, and they are very heterogeneous and limited in quantity. We will use our extensive experience with developing bioreactor protocols to produce defined adult stem cell (ASC) populations to now engineer scaled-up processes for the reproducible generation of targeted ASC-derived EVs. It is increasingly believed that many of the positive outcomes reported following the implantation of ASCs to treat disease may actually be due to the EVs the cells are producing. Our program will result in robust bioprocesses capable of supplying large quantities of defined EVs to researchers who are trying to develop new therapies against human and animal diseases. (2) Current approaches to collecting EVs are inefficient, highly user-dependent, and result in very low yields. We have made progress on developing a simple and cost-effective microfluidic device which can operate at high flow rates to efficiently and reproducibly separate and isolate EVs from biological fluids and cell culture fluids. We plan to further refine this technology as it has the potential to become the standard EV separation process used by all researchers in this fast-growing field. The requested ExoView R100 can accurately quantify, as well as physically/functionally characterize EVs. This device, which would be unique in Canada, will enable us to develop, validate and translate our EV production and separation technologies, and is crucial to ensuring the progression and success of this research program. The ExoView will be accessible, with provided training, to the diverse and rapidly growing group of EV researchers from different disciplines both within and outside the University of Calgary. The resulting technologies and trained personnel will contribute to Canada becoming a global leader in this exciting new field.